Triple HER2 blockade combined with nab‐paclitaxel did not significantly improve the tpCR rate compared with dual TP therapy in the neoadjuvant treatment of HER2‐positive breast cancer and was associated with a high incidence of severe diarrhea. This evidence concerns the gene ERBB2 and breast cancer.